LIVIVO - Search results -

Search results

Result 1 - 10 of total 99

Search options

Article: Antimicrobial Effect of Zn

Hutchings, Carmel / Prokocimer Yair, Zafnat / Reifen, Ram / Shemesh, Moshe

2021 Volume 10, Issue 3

Abstract: Donor human milk (HM) obtained at HM banks is exceptionally crucial for the feeding and treatment of preterm infants. Bacterial contaminations of HM in various stages of its handling are very common and can lead to disqualification of donations or severe ...

Abstract	Donor human milk (HM) obtained at HM banks is exceptionally crucial for the feeding and treatment of preterm infants. Bacterial contaminations of HM in various stages of its handling are very common and can lead to disqualification of donations or severe infections in worse cases. Hence, HM donations are subject to strict bacteriological evaluations pre- and post-pasteurization. The main contaminating species vary between countries, banks and donors and even exhibit inter-individual variation. We initiated an assessment of the bacteriological composition of HM donated by women hospitalized in a neonatal intensive care unit in Israel. The most common bacterium identified was
Language	English
Publishing date	2021-03-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2704223-6
ISSN	2304-8158
ISSN	2304-8158
DOI	10.3390/foods10030637
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Prokocimer, Miron / Molchadsky, Alina / Rotter, Varda

Blood

2017 Volume 130, Issue 6, Page(s) 699–712

Abstract: The heterogeneous nature of acute myeloid leukemia (AML) and its poor prognosis necessitate therapeutic improvement. Current advances in AML research yield important insights regarding AML genetic, epigenetic, evolutional, and clinical diversity, all in ... ...

Abstract	The heterogeneous nature of acute myeloid leukemia (AML) and its poor prognosis necessitate therapeutic improvement. Current advances in AML research yield important insights regarding AML genetic, epigenetic, evolutional, and clinical diversity, all in which dysfunctional p53 plays a key role. As p53 is central to hematopoietic stem cell functions, its aberrations affect AML evolution, biology, and therapy response and usually predict poor prognosis. While in human solid tumors
MeSH term(s)	Adult ; Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; DNA Damage/drug effects ; Gene Expression Regulation, Leukemic/drug effects ; Genomic Instability/drug effects ; Hematopoiesis/drug effects ; Humans ; Karyopherins/genetics ; Karyopherins/metabolism ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/metabolism ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Molecular Targeted Therapy/methods ; Mutation/drug effects ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Nucleophosmin ; Protein Interaction Maps/drug effects ; Receptors, Cytoplasmic and Nuclear/genetics ; Receptors, Cytoplasmic and Nuclear/metabolism ; Signal Transduction/drug effects ; Translocation, Genetic ; Tumor Suppressor Protein p53/analysis ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; fms-Like Tyrosine Kinase 3/genetics ; fms-Like Tyrosine Kinase 3/metabolism ; Exportin 1 Protein
Chemical Substances	Antineoplastic Agents ; Karyopherins ; MicroRNAs ; Nuclear Proteins ; Receptors, Cytoplasmic and Nuclear ; Tumor Suppressor Protein p53 ; Nucleophosmin (117896-08-9) ; FLT3 protein, human (EC 2.7.10.1) ; fms-Like Tyrosine Kinase 3 (EC 2.7.10.1)
Language	English
Publishing date	2017-06-12
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2017-02-763086
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Dynamic

Golan, Shay / Aviv, Tzach / Groshar, David / Yakimov, Maxim / Zohar, Yaniv / Prokocimer, Yoad / Nadu, Andrei / Baniel, Jack / Domachevsky, Liran / Bernstine, Hanna

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

2020 Volume 62, Issue 6, Page(s) 773–778

Abstract: The potential role of prostate-specific membrane antigen (PSMA) PET/CT in non-prostate cancer tumors has shown promising results. We examined the performance of ... ...

Abstract	The potential role of prostate-specific membrane antigen (PSMA) PET/CT in non-prostate cancer tumors has shown promising results. We examined the performance of dynamic
MeSH term(s)	Female ; Gallium Isotopes ; Gallium Radioisotopes ; Humans ; Kidney Neoplasms/diagnostic imaging ; Kidney Neoplasms/pathology ; Kidney Neoplasms/surgery ; Male ; Pilot Projects ; Positron Emission Tomography Computed Tomography ; Prospective Studies
Chemical Substances	Gallium Isotopes ; Gallium Radioisotopes ; gallium 68 PSMA-11
Language	English
Publishing date	2020-10-23
Publishing country	United States
Document type	Clinical Trial ; Journal Article
ZDB-ID	80272-4
ISSN	1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
ISSN (online)	1535-5667
ISSN	0097-9058 ; 0161-5505 ; 0022-3123
DOI	10.2967/jnumed.120.251272
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 328: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cytoplasmic sequestration of wild-type p53 in a patient with therapy-related resistant AML: first report.

Prokocimer, Miron / Peller, Shoshana

Medical oncology (Northwood, London, England)

2011 Volume 29, Issue 2, Page(s) 1148–1150

Abstract: p53 inactivation is a key factor in human tumorigenesis and chemotherapy resistance. The traditionally described mechanisms of p53 inactivation in acute myeloid leukemia (AML) include TP53 mutations and abrogation of p53 pathway. Malfunction of wild-type ...

Abstract	p53 inactivation is a key factor in human tumorigenesis and chemotherapy resistance. The traditionally described mechanisms of p53 inactivation in acute myeloid leukemia (AML) include TP53 mutations and abrogation of p53 pathway. Malfunction of wild-type (wt) p53, due to its cytoplasmic mislocalization, has been described, thus far, only in solid tumors. Herein, we present a patient with therapy-related resistant AML, monosomal karyotype, wt TP53, and cytoplasmic sequestration of p53 protein. Proposed mechanisms of p53 mislocalization and their probable clinical and therapeutic implications are discussed. In view of the relative rareness of TP53 mutations in AML, the cytoplasmic sequestration of p53 protein offers an additional inactivating mechanism, which might be more frequent than currently diagnosed. This notion warrants confirmation by prospective studies in large cohorts of patients. We recommend that evaluation of p53 subcellular localization and function should be included in the diagnostic work-up of AML with wt p53.
MeSH term(s)	Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytoplasm/metabolism ; DNA, Neoplasm/genetics ; Drug Resistance, Neoplasm ; Humans ; Immunoenzyme Techniques ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Male ; Polymerase Chain Reaction ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism
Chemical Substances	DNA, Neoplasm ; TP53 protein, human ; Tumor Suppressor Protein p53
Language	English
Publishing date	2011-03-27
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1201189-7
ISSN	1559-131X ; 0736-0118 ; 1357-0560
ISSN (online)	1559-131X
ISSN	0736-0118 ; 1357-0560
DOI	10.1007/s12032-011-9916-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1899: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Hutchinson-Gilford progeria syndrome through the lens of transcription.

Prokocimer, Miron / Barkan, Rachel / Gruenbaum, Yosef

Aging cell

2013 Volume 12, Issue 4, Page(s) 533–543

Abstract: Lamins are nuclear intermediate filaments. In addition to their structural roles, they are implicated in basic nuclear functions such as chromatin organization, DNA replication, transcription, DNA repair, and cell-cycle progression. Mutations in human ... ...

Abstract	Lamins are nuclear intermediate filaments. In addition to their structural roles, they are implicated in basic nuclear functions such as chromatin organization, DNA replication, transcription, DNA repair, and cell-cycle progression. Mutations in human LMNA gene cause several diseases termed laminopathies. One of the laminopathic diseases is Hutchinson-Gilford progeria syndrome (HGPS), which is caused by a spontaneous mutation and characterized by premature aging. HGPS phenotypes share certain similarities with several apparently comparable medical conditions, such as aging and atherosclerosis, with the conspicuous absence of neuronal degeneration and cancer rarity during the short lifespan of the patients. Cell lines from HGPS patients are characterized by multiple nuclear defects, which include abnormal morphology, altered histone modification patterns, and increased DNA damage. These cell lines provide insight into the molecular pathways including senescence that require lamins A and B1. Here, we review recent data on HGPS phenotypes through the lens of transcriptional deregulation caused by lack of functional lamin A, progerin accumulation, and lamin B1 silencing.
MeSH term(s)	Adult Stem Cells/metabolism ; Adult Stem Cells/pathology ; Cell Nucleus/genetics ; Cell Nucleus/metabolism ; Chromatin Assembly and Disassembly ; DNA Repair ; Gene Silencing ; Humans ; Lamin Type A/genetics ; Lamin Type A/metabolism ; Lamin Type B/genetics ; Lamin Type B/metabolism ; Mechanotransduction, Cellular ; Nuclear Proteins/genetics ; Nuclear Proteins/metabolism ; Phenotype ; Progeria/genetics ; Progeria/metabolism ; Progeria/pathology ; Protein Precursors/genetics ; Protein Precursors/metabolism ; Telomere/genetics ; Telomere/metabolism ; Transcription, Genetic
Chemical Substances	LMNA protein, human ; Lamin Type A ; Lamin Type B ; Nuclear Proteins ; Protein Precursors ; prelamin A
Language	English
Publishing date	2013-04-19
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2113083-8
ISSN	1474-9726 ; 1474-9718
ISSN (online)	1474-9726
ISSN	1474-9718
DOI	10.1111/acel.12070
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6581: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.

Corey, Ralph / Moran, Gregory / Goering, Richard / Bensaci, Mekki / Sandison, Taylor / De Anda, Carisa / Prokocimer, Philippe

Diagnostic microbiology and infectious disease

2019 Volume 94, Issue 3, Page(s) 277–286

Abstract: We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure ... ...

Abstract	We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/administration & dosage ; Child ; Clinical Trials, Phase III as Topic ; Double-Blind Method ; Female ; Gram-Positive Bacterial Infections/drug therapy ; Humans ; Linezolid/administration & dosage ; Male ; Middle Aged ; Oxazolidinones/administration & dosage ; Randomized Controlled Trials as Topic ; Skin Diseases, Bacterial/drug therapy ; Soft Tissue Infections/drug therapy ; Tetrazoles/administration & dosage ; Treatment Outcome ; Young Adult
Chemical Substances	Anti-Bacterial Agents ; Oxazolidinones ; Tetrazoles ; tedizolid (97HLQ82NGL) ; Linezolid (ISQ9I6J12J)
Language	English
Publishing date	2019-01-30
Publishing country	United States
Document type	Journal Article
ZDB-ID	604920-5
ISSN	1879-0070 ; 0732-8893
ISSN (online)	1879-0070
ISSN	0732-8893
DOI	10.1016/j.diagmicrobio.2019.01.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1845: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The added value of peripheral blood cell morphology in the diagnosis and management of infectious diseases--part 1: basic concepts.

Prokocimer, M / Potasman, I

Postgraduate medical journal

2008 Volume 84, Issue 997, Page(s) 579–585

Abstract: As automated blood cell analysers and sophisticated diagnostic technologies become widespread, requests for peripheral blood smear (PBS) examination--for the diagnosis of infectious diseases--diminish. Yet, PBS examination can provide rapid and ... ...

Abstract	As automated blood cell analysers and sophisticated diagnostic technologies become widespread, requests for peripheral blood smear (PBS) examination--for the diagnosis of infectious diseases--diminish. Yet, PBS examination can provide rapid and invaluable information on infection--host susceptibility, aetiology, severity, and systemic impact. Besides direct visualisation of certain microorganisms (for example, Plasmodium, Ehrlichia), PBS examination may detect characteristic footprints left by various infections on the morphology of blood cells, thus yielding the cytologic clues of the disease (for example, Döhle bodies, haemophagocytosis). Additionally, PBS examination may disclose certain infection predisposing conditions (for example, May-Hegglin anomaly, hyposplenism), and several infection related haematological and systemic complications. Combined with a careful medical history and physical examination data, all this information may yield a speedy diagnosis, a rationalised diagnostic work-up, and timely initiation of treatment. The intention of the following review is to highlight the value of PBS, and recommend that PBS examination should be fostered in the diagnostic work-up of infectious diseases.
MeSH term(s)	Anemia/pathology ; Cell Aggregation ; Humans ; Infection/pathology ; Infection/therapy ; Leukocytes, Mononuclear/pathology ; Lymphocytosis/pathology
Language	English
Publishing date	2008-11
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	80325-x
ISSN	1469-0756 ; 0032-5473
ISSN (online)	1469-0756
ISSN	0032-5473
DOI	10.1136/pgmj.2008.069609
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.340: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The added value of peripheral blood cell morphology in the diagnosis and management of infectious diseases--part 2: illustrative cases.

Potasman, I / Prokocimer, M

Postgraduate medical journal

2008 Volume 84, Issue 997, Page(s) 586–589

Abstract: The previous review dealt with the diagnostic yield of peripheral blood smear examination with regard to diagnosis of infectious diseases. In addition to the clinical data, it can provide information of major clinical significance. At times, it can even ... ...

Abstract	The previous review dealt with the diagnostic yield of peripheral blood smear examination with regard to diagnosis of infectious diseases. In addition to the clinical data, it can provide information of major clinical significance. At times, it can even replace additional, costly and time-consuming diagnostic modalities. The following clinical vignettes, which are discussed briefly, support these arguments.
MeSH term(s)	Aged, 80 and over ; Cytomegalovirus Infections/pathology ; Diagnosis, Differential ; Epstein-Barr Virus Infections/pathology ; Gram-Negative Bacterial Infections/pathology ; Humans ; Infection/pathology ; Infection/therapy ; Leukemia, Large Granular Lymphocytic/pathology ; Leukocytes, Mononuclear/pathology ; Lymphohistiocytosis, Hemophagocytic/pathology ; Meningococcal Infections/pathology ; Middle Aged ; Parvoviridae Infections/pathology ; Red-Cell Aplasia, Pure/pathology ; Spherocytosis, Hereditary/pathology ; Splenic Diseases/pathology ; Young Adult
Language	English
Publishing date	2008-11
Publishing country	England
Document type	Journal Article
ZDB-ID	80325-x
ISSN	1469-0756 ; 0032-5473
ISSN (online)	1469-0756
ISSN	0032-5473
DOI	10.1136/pgmj.2008.069617
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.340: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.

Hardalo, Cathy / Lodise, Thomas P / Bidell, Monique / Flanagan, Shawn / De Anda, Carisa / Anuskiewicz, Steven / Prokocimer, Philippe

Expert opinion on drug safety

2018 Volume 17, Issue 4, Page(s) 359–367

Abstract: Background: We evaluated safety and tolerability of tedizolid phosphate at the 200-mg once-daily dose approved for 6-day treatment of skin and skin-structure infections.: Research design and methods: Clinical adverse event (AE) and laboratory data ... ...

Abstract	Background: We evaluated safety and tolerability of tedizolid phosphate at the 200-mg once-daily dose approved for 6-day treatment of skin and skin-structure infections. Research design and methods: Clinical adverse event (AE) and laboratory data were pooled across completed clinical studies (13 phase 1, two phase 2, and two phase 3), for all participants who received ≥1 dose of tedizolid 200 mg, linezolid 600 mg (phase 3 only), or placebo (phase 1 only). Results: 1280 participants received tedizolid (phase 1: n = 355; phase 2/3: n = 925). In total, 13% received >6 doses of tedizolid (range: 7-21); in phase 2/3, 94% of participants received ≥5 doses (range: 5-10). Drug-related AEs occurred in 27% of participants (most commonly gastrointestinal reactions in 13% of participants and headache in 4%). Most AEs were mild-moderate in severity; <1% of participants discontinued treatment due to AEs. Tedizolid and linezolid had similar frequency, severity, and types of drug-related AEs. Tolerability in clinically important subpopulations (obese, n = 346; elderly, n = 99; renal impairment, n = 40; hepatic disease/impairment, n = 294) appeared comparable to the overall population. Conclusions: Tedizolid, given orally or intravenously at 200 mg, has a favorable safety profile. Clinical trial and postmarketing experience with treatment ≥7 days is limited.
MeSH term(s)	Acute Disease ; Administration, Intravenous ; Administration, Oral ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Clinical Trials as Topic ; Humans ; Linezolid/administration & dosage ; Linezolid/adverse effects ; Organophosphates/administration & dosage ; Organophosphates/adverse effects ; Oxazoles/administration & dosage ; Oxazoles/adverse effects ; Severity of Illness Index ; Skin Diseases, Bacterial/drug therapy
Chemical Substances	Anti-Bacterial Agents ; Organophosphates ; Oxazoles ; Linezolid (ISQ9I6J12J) ; tedizolid phosphate (O7DRJ6R4DW)
Language	English
Publishing date	2018-03-12
Publishing country	England
Document type	Comparative Study ; Journal Article ; Meta-Analysis ; Review
ZDB-ID	2088728-0
ISSN	1744-764X ; 1474-0338
ISSN (online)	1744-764X
ISSN	1474-0338
DOI	10.1080/14740338.2018.1446939
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6096: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.

Das, Debaditya / Tulkens, Paul M / Mehra, Purvi / Fang, Edward / Prokocimer, Philippe

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

2013 Volume 58 Suppl 1, Page(s) S51–7

Abstract: The novel oxazolidinone tedizolid phosphate is in late-stage clinical development. In an effort to improve efficacy and safety, the adverse event profile and safety aspects of tedizolid phosphate have been evaluated in several preclinical animal models ... ...

Abstract	The novel oxazolidinone tedizolid phosphate is in late-stage clinical development. In an effort to improve efficacy and safety, the adverse event profile and safety aspects of tedizolid phosphate have been evaluated in several preclinical animal models and through ongoing clinical trials. Early dose-ranging studies demonstrated a favorable overall adverse event profile and low thrombocytopenia rates, which have been consistently confirmed in phase 2 and 3 clinical trials. Pharmacokinetic modeling suggests a lower potential for monoamine oxidase interaction, and animal and human subject testing has confirmed these predictions. Studies in special patient populations showed a consistent and predictable pharmacokinetic profile across age groups and comorbid conditions, without evidence of increased incidence of adverse effects over matched controls. The favorable safety profile makes tedizolid phosphate an important new option for the management of serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus.
MeSH term(s)	Animals ; Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; Clinical Trials as Topic ; Disease Models, Animal ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Humans ; Organophosphates/adverse effects ; Organophosphates/therapeutic use ; Oxazoles/adverse effects ; Oxazoles/therapeutic use ; Staphylococcal Skin Infections/drug therapy
Chemical Substances	Anti-Bacterial Agents ; Organophosphates ; Oxazoles ; tedizolid phosphate (O7DRJ6R4DW)
Language	English
Publishing date	2013-12-11
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1099781-7
ISSN	1537-6591 ; 1058-4838
ISSN (online)	1537-6591
ISSN	1058-4838
DOI	10.1093/cid/cit618
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1505: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 480: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito